Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.

Titanium implant surfaces with rough microtopographies exhibit increased pullout strength in vivo suggesting increased bone-to-implant contact. This is supported by in vitro studies showing that as surface microroughness increases, osteoblast proliferation decreases whereas differentiation increases. Differentiation is further enhanced on microrough surfaces by factors stimulating osteogenesis including 1alpha,25(OH)2D3. Levels of PGE2 and TGF-beta1 are increased in cultures grown on rough microtopographies; this surface effect is enhanced synergistically by 1alpha,25(OH)2D3-treatment. PGE2 and TGF-beta1 regulate osteoclasts as well as osteoblasts, suggesting that surface microtopography may modulate release of other factors from osteoblasts that regulate osteoclasts. To test this hypothesis, we examined the effects of substrate microarchitecture on production of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL), which have been identified as a key regulatory system of bone remodeling. We also examined the production of 1alpha,25(OH)2D3, which regulates osteoblast differentiation and osteoclastogenesis. MG63 osteoblast-like cells were grown on either tissue culture plastic or titanium disks of different surface microtopographies: PT (Ra < 0.2 microm), SLA (Ra = 4 microm), and TPS (Ra = 5 microm). At confluence, cultures were treated for 24 h with 0, 10(-8) M or 10(-7) M 1alpha,25(OH)2D3. RANKL and OPG were determined at the transcriptional level by RT-PCR and real time PCR and soluble RANKL, OPG and 1alpha,25(OH)2D3 in the conditioned media were measured using immunoassay kits. Cell number was reduced on SLA and TPS surfaces and 1alpha,25(OH)2D3 caused further decreases. OPG mRNA levels increased on rougher surfaces and 1alpha,25(OH)2D3 treatment caused a further synergistic increase. While the cells expressed RANKL mRNA, levels were low and independent of surface microtopography. OPG protein was greater when cells were grown on SLA and TPS. 1alpha,25(OH)2D3 increased OPG by 50% on the smooth Ti surface but on SLA, 10(-8) M 1alpha,25(OH)2D3 caused a 100% increase and 10(-7) M 1alpha,25(OH)2D3 increased OPG by 200%. On TPS 10(-7) M 1alpha,25(OH)2D3 increased OPG 350%. Soluble RANKL was not detected in the conditioned media of any of the cultures. 1alpha,25(OH)2D3 was produced endogenously and levels were positively correlated with surface roughness. Thus, on surfaces with rough microtopographies, osteoblasts secrete factors that enhance osteoblast differentiation while decreasing osteoclast formation and activity.

[1]  D. Lacey,et al.  Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. , 1999, Endocrinology.

[2]  J. Ong,et al.  Effect of transforming growth factor-beta on osteoblast cells cultured on 3 different hydroxyapatite surfaces. , 1999, The International journal of oral & maxillofacial implants.

[3]  R. Palmer,et al.  Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. , 2002, Clinical oral implants research.

[4]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Raisz,et al.  Biphasic effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: interaction with cortisol. , 1990, Endocrinology.

[6]  T. Martin,et al.  Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. , 1999, Bone.

[7]  S. Mochizuki,et al.  Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. , 1998, Biochemical and biophysical research communications.

[8]  B D Boyan,et al.  Effect of titanium surface roughness on proliferation, differentiation, and protein synthesis of human osteoblast-like cells (MG63). , 1995, Journal of biomedical materials research.

[9]  S. vandeVondele,et al.  RGD-containing peptide GCRGYGRGDSPG reduces enhancement of osteoblast differentiation by poly(L-lysine)-graft-poly(ethylene glycol)-coated titanium surfaces. , 2004, Journal of biomedical materials research. Part A.

[10]  B. Kwon,et al.  TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  K. Ikeda,et al.  Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells* , 1998, The Journal of Biological Chemistry.

[12]  B. Boyan,et al.  Inhibition of cyclooxygenase by indomethacin modulates osteoblast response to titanium surface roughness in a time-dependent manner. , 2001, Clinical oral implants research.

[13]  L. Bonewald,et al.  Differential regulation of prostaglandin E2 synthesis and phospholipase A2 activity by 1,25-(OH)2D3 in three osteoblast-like cell lines (MC-3T3-E1, ROS 17/2.8, and MG-63). , 1992, Bone.

[14]  J. Ong,et al.  Osteoblast responses to BMP-2-treated titanium in vitro. , 1997, The International journal of oral & maxillofacial implants.

[15]  G. Gronowicz,et al.  Response of human osteoblasts to implant materials: Integrin‐mediated adhesion , 1996, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[16]  D. Dean,et al.  Physiological Importance of the 1,25(OH)2D3 Membrane Receptor and Evidence for a Membrane Receptor Specific for 24,25(OH)2D3 , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  B D Boyan,et al.  Surface roughness modulates the local production of growth factors and cytokines by osteoblast-like MG-63 cells. , 1996, Journal of biomedical materials research.

[18]  G S Stein,et al.  Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. , 1993, Endocrine reviews.

[19]  B. Boyan,et al.  Local factor production by MG63 osteoblast-like cells in response to surface roughness and 1,25-(OH)2D3 is mediated via protein kinase C- and protein kinase A-dependent pathways. , 2001, Biomaterials.

[20]  L. Bonewald,et al.  Effects of combining transforming growth factor beta and 1,25-dihydroxyvitamin D3 on differentiation of a human osteosarcoma (MG-63). , 1992, The Journal of biological chemistry.

[21]  K. Hirokawa,et al.  Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus. , 2001, Endocrinology.

[22]  C. Ohlsson,et al.  Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. , 1998, Biochemical and biophysical research communications.

[23]  D. Dean,et al.  Prostaglandins mediate the effects of titanium surface roughness on MG63 osteoblast-like cells and alter cell responsiveness to 1 alpha,25-(OH)2D3. , 1998, Journal of biomedical materials research.

[24]  H. Yasuda,et al.  Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis , 2002, Journal of Bone and Mineral Metabolism.

[25]  G. Howard,et al.  Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. , 1981, The Journal of biological chemistry.

[26]  P. Young,et al.  Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. , 1997, Gene.

[27]  T. Martin,et al.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Boyan,et al.  Response of normal female human osteoblasts (NHOst) to 17beta-estradiol is modulated by implant surface morphology. , 2002, Journal of biomedical materials research.

[29]  S D Cook,et al.  An evaluation of variables influencing implant fixation by direct bone apposition. , 1985, Journal of biomedical materials research.

[30]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[31]  C. Lohmann,et al.  Response of MG63 osteoblast-like cells to titanium and titanium alloy is dependent on surface roughness and composition. , 1998, Biomaterials.

[32]  M. Sporn,et al.  Transforming growth factor-beta: biological function and chemical structure. , 1986, Science.

[33]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[34]  B. Riggs,et al.  The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated* *This work was supported by Grant AG-04875 from the National Institute on Aging. , 2000, Endocrinology.

[35]  N. Baldini,et al.  Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. , 2002, Biomaterials.

[36]  L. Bonewald,et al.  Maturation State Determines the Response of Osteogenic Cells to Surface Roughness and 1,25‐Dihydroxyvitamin D3 , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[38]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[39]  Marcus Textor,et al.  Wavelength-dependent measurement and evaluation of surface topographies: application of a new concept of window roughness and surface transfer function , 2000 .

[40]  B. Boyan,et al.  Regulation of prostaglandin E2 production by vitamin D metabolites in growth zone and resting zone chondrocyte cultures is dependent on cell maturation. , 1992, Bone.

[41]  B. Boyan,et al.  Both cyclooxygenase-1 and cyclooxygenase-2 mediate osteoblast response to titanium surface roughness. , 2001, Journal of biomedical materials research.

[42]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[43]  N. Ohashi,et al.  Isolation, identification and biological activity of 24R,25-dihydroxy-3-epi-vitamin D3: a novel metabolite of 24R,25-dihydroxyvitamin D3 produced in rat osteosarcoma cells (UMR 106). , 2001, Journal of nutritional science and vitaminology.

[44]  G. Nicholson,et al.  Expression of functional RANK on mature rat and human osteoclasts , 1999, FEBS letters.

[45]  A. Harris,et al.  Anomalous preferences of cultured macrophages for hydrophobic and roughened substrata. , 1981, Journal of cell science.

[46]  L. Bonewald,et al.  Evidence for distinct membrane receptors for 1α,25-(OH)2D3 and 24R,25-(OH)2D3 in osteoblasts , 2002, Steroids.

[47]  K. Ikeda,et al.  Prostaglandin E2 Induces Expression of Receptor Activator of Nuclear Factor–κB Ligand/Osteoprotegrin Ligand on Pre‐B Cells: Implications for Accelerated Osteoclastogenesis in Estrogen Deficiency , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[48]  B. Riggs,et al.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.

[49]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[50]  S. Ferguson,et al.  Biomechanical comparison of the sandblasted and acid-etched and the machined and acid-etched titanium surface for dental implants. , 2002, Journal of biomedical materials research.

[51]  B. Boyan,et al.  Titanium surface roughness alters responsiveness of MG63 osteoblast‐like cells to 1α,25‐(OH)2D3 , 1998 .

[52]  D. Brunette,et al.  The effects of implant surface topography on the behavior of cells. , 1988, The International journal of oral & maxillofacial implants.

[53]  D. L. Cochran,et al.  Osteoblast-Mediated Mineral Deposition in Culture is Dependent on Surface Microtopography , 2002, Calcified Tissue International.